Zai Lab Ltd(ZLAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZLAB Zai Lab Ltd

Market Closed 02-07 16:00:00 EST

27.53

-0.28

-1.01%

盘后27.53

+0.000.00%

17:02 EST

High28.03	Low27.09	Vol495.41K
Open27.84	D1 Closing27.81	Amplitude3.39%
Mkt Cap3.00B	Tradable Cap2.74B	Total Shares108.94M
T/O13.63M	T/O Rate0.50%	Tradable Shares99.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"Zai Lab Ltd","latestPrice":27.53,"timestamp":1738962000000,"preClose":27.81,"halted":0,"volume":495413,"hourTrading":{"tag":"盘后","latestPrice":27.53,"preClose":27.53,"latestTime":"17:02 EST","volume":48185,"amount":1326533.05,"timestamp":1738965772592},"delay":0,"floatShares":99544832,"shares":108937154,"eps":-2.77706,"marketStatus":"Market Closed","change":-0.28,"latestTime":"02-07 16:00:00 EST","open":27.84,"high":28.0339,"low":27.09,"amount":13633266.879108999,"amplitude":0.033941,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.77706,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739178000000},"marketStatusCode":7,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":27.81,"preHourTrading":{"tag":"盘前","latestPrice":28.08,"preClose":27.81,"latestTime":"08:37 EST","volume":108,"amount":3032.64,"timestamp":1738935463777},"postHourTrading":{"tag":"盘后","latestPrice":27.53,"preClose":27.53,"latestTime":"17:02 EST","volume":48185,"amount":1326533.05,"timestamp":1738965772592},"volumeRatio":0.6092614634990666,"impliedVol":0.6686,"impliedVolPercentile":0.4661},"requestUrl":"/m/hq/s/ZLAB/wiki","defaultTab":"wiki","newsList":[{"id":"2506590285","title":"Press Release: Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2506590285","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506590285?lang=en_us&edition=fundamental","pubTime":"2025-01-28 20:34","pubTimestamp":1738067640,"startTime":"0","endTime":"0","summary":"Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025. - Company to host conference call and webcast on February 27, at 8:00 a.m. ET . Zai Lab Limited  today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET .All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.A replay will be available shortly after the call and can be accessed by visiting the Company's website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4531","BK4548","BK4139","BK4585","ZLAB","BK4588"],"gpt_icon":0},{"id":"2505010984","title":"Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2505010984","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505010984?lang=en_us&edition=fundamental","pubTime":"2025-01-23 23:45","pubTimestamp":1737647156,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were edging lower on Thursday morning, down 0.2% to 2,123.24 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by semiconductor maker Himax Technologies  and after-school education and tutoring company TAL Education , which advanced 19% and 16%, respectively.They were followed by exam preparation and tutoring company Gaotu Techedu  and tech company Tuya , which climbed 4.3% and 2.6%, respectively.The decliners from North Asia were led by holographic products provider WiMi  and apartment rental platform XChange , which fell 8.2% and 5.2%, respectively.They were followed by biopharmaceutical company Zai Lab  and solar module manufacturer JinkoSolar , which dropped 3.3% and 1.8%, respectively.From South Asia, the gainers were led by tech companies Wipro  and Infosys , which rose 1.6% and 0.5%, respectively.The decliners from South Asia were led by pharmaceutical company Dr Reddy's Laboratories , which fell 5%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GOTU","LU0456842615.SGD","XHG","BK4531","LU0708995666.HKD","RDY","RDY.AU","LU2177674079.SGD","BK4533","BK4510","LU0868486357.SGD","HIMX","ZLAB","LU1791710582.SGD","WIT","SG9999014013.SGD","LU2226246903.HKD","LU0630378429.USD","LU0431992006.USD","LU2279701549.SGD","LU0390134368.USD","LU0918141887.USD","TUYA","LU0541501648.USD","TAL.AU","TAL","BK4523","LU1323998911.USD","WIMI","BK4535","IE00BYTNYM70.SGD","BK4173","LU1105468828.SGD","BK4596","BK4139","INFY","LU0898667661.SGD","LU2008162690.USD","IE00B3M56506.USD","BK4585","IE00B0JY6M65.USD","IE00B7N09G41.SGD","HDB","BK4233","LU1854103824.USD","LU0531971678.HKD","JKS","AFG","LU0197229882.USD","BK4548"],"gpt_icon":0},{"id":"2505406499","title":"Zai Lab Says FDA Grants Orphan Drug Designation for ZL-1310","url":"https://stock-news.laohu8.com/highlight/detail?id=2505406499","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505406499?lang=en_us&edition=fundamental","pubTime":"2025-01-23 17:31","pubTimestamp":1737624668,"startTime":"0","endTime":"0","summary":"Zai Lab  said late Wednesday the US Food and Drug Administration has granted orphan drug designation to ZL-1310 for the treatment of small cell lung cancer following data from an ongoing phase 1a/1b study.ZL-1310 will be eligible for certain development incentives, including tax credits for certain clinical trials and the potential to receive a seven-year US market exclusivity period upon product approval, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","BK4548","BK4139","BK4531","ZLAB","BK4588","BK4585"],"gpt_icon":0},{"id":"2505059419","title":"Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505059419","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505059419?lang=en_us&edition=fundamental","pubTime":"2025-01-23 14:41","pubTimestamp":1737614466,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks.In this article, we are going to take a look at where Zai Lab Limited  stands against Andreas Halvorsen's other long-term stock picks.Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world. Known for his disciplined investment approach and ability to identify long-term opportunities, Halvorsen has built a reputation as a leader in the financial industry. Halvorsen was born in 1961 in Norway. He attended the Norwegian Naval Academy, where he developed a strong work ethic, leadership skills, and a disciplined mindset. After completing his military service, Halvorsen decided to pursue a career in finance. He enrolled at Williams College, a prestigious liberal arts institution in the United States, and graduated with a degree in economics. Halvorsen later attended the Stanford Graduate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-andreas-halvorsen-bullish-zai-064106285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BNTX","BK4139","BK4551","BK4568","ZAILF","BK4531","BK4548","BK4588","BK4526","ZLAB","BK4535"],"gpt_icon":0},{"id":"2505191032","title":"Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505191032","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505191032?lang=en_us&edition=fundamental","pubTime":"2025-01-23 12:15","pubTimestamp":1737605700,"startTime":"0","endTime":"0","summary":"SHANGHAI & CAMBRIDGE, Mass., January 23, 2025----Zai Lab Limited  today announced the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate , for the treatment of small cell lung cancer .\"Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment options with improved efficacy, safety and ready access in tertiary care and community settings,\" said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. \"ZL-1310 has demonstrated promising objective response rates and a favorable safety profile from the ongoing Phase 1 trial in patients with recurrent SCLC recently disclosed. We look forward to continuing to advance the clinical development of this promising asset across lines of therapy in SCLC and other DLL3-expressing tumors.\". ZL-1310 will be eligible for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-receives-orphan-drug-041500698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4231","BK4588","BK4585","ZLAB","BK4526","BK4139","ADC","BK4548","BK4531","ODD","BK4183"],"gpt_icon":0},{"id":"2505062276","title":"High Growth Tech Stocks To Explore In January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505062276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505062276?lang=en_us&edition=fundamental","pubTime":"2025-01-21 22:07","pubTimestamp":1737468464,"startTime":"0","endTime":"0","summary":"The United States market has shown robust performance with a 3.1% increase over the last week and a 24% rise over the past year, while earnings are projected to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability, aligning well with these positive market conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 229 stocks from our US High Growth Tech and AI Stocks screener.NasdaqGM:ZLAB Earnings and Revenue Growth as at Jan 2025. Overview: CarGurus, Inc. operates an online automotive platform for buying and selling vehicles in the United States and internationally, with a market cap of approximately $3.92 billion.Operations: The company generates revenue primarily through its U.S. Marketplace segment, contributing $709.19 million, and its Digital Wholesale segment, adding $120.31 million. The business focus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-explore-140744563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLAB","BK4526","DOCN","BK4585","CARG","BK4139","BK4548","BK4116","BK4531","BK4588"],"gpt_icon":0},{"id":"2505257704","title":"Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505257704","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505257704?lang=en_us&edition=fundamental","pubTime":"2025-01-21 08:06","pubTimestamp":1737417981,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited  stands against the other hot stocks.What's the US Stock Market Like in 2025?While the stock market in the United States remained closed on January 20 for Martin Luther King, Jr. Day, the day was happening with Donald Trump's inauguration on the same date. Previously, the stock market enjoyed a rally following Trump's win as the election uncertainty dissolved and the investor sentiment experienced a boost, looking forward to a pro-business environment.At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 smal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-analysts-bullish-zai-lab-000621699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZAILF","NVIW.SI","BK4585","USJW.SI",".IXIC","BK4548","USAW.SI","QID","BK4526","PSQ","BK4139","NQmain","BK4588","QLD","TSYW.SI","SQQQ","TQQQ","BK4531","ZLAB","MNQmain"],"gpt_icon":1},{"id":"2504055494","title":"Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2504055494","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504055494?lang=en_us&edition=fundamental","pubTime":"2025-01-20 18:48","pubTimestamp":1737370089,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Zai Lab Limited's  business as it appears the company may be on the cusp of a considerable accomplishment. Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. With the latest financial year loss of US$335m and a trailing-twelve-month loss of US$271m, the US$2.8b market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which Zai Lab will turn a profit, with the big question being “when will the company breakeven?”Below we will provide a high-level summary of the industry analysts’ expectations for the company.According to the 14 industry analysts covering Zai Lab, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$70m in 2026. The company is therefore projected to breakeven just over a year from today. In order ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/market-sentiment-around-loss-making-104809422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","NQmain","NVIW.SI","IE00BKPKM429.USD","TQQQ","QID",".IXIC","NDAQ","IE00B64PRP62.GBP","TSYW.SI","IE00BGHQF748.EUR","USAW.SI","ZLAB","BK4585","PSQ","LU2210149790.SGD","BK4112","SQQQ","BK4139","BK4548","BK4526","USJW.SI","BK4531","MNQmain","QLD","BK4588","LU2095319765.USD","ZAILF"],"gpt_icon":1},{"id":"2504435118","title":"Sector Update: Health Care Stocks Softer Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2504435118","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504435118?lang=en_us&edition=fundamental","pubTime":"2025-01-18 03:00","pubTimestamp":1737140457,"startTime":"0","endTime":"0","summary":"Health care stocks declined Friday afternoon with the NYSE Health Care Index down 0.6% and the Health Care Select Sector SPDR Fund (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.3%.In co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","BK4599","LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK7104","IE00BKVL7J92.USD","BK4581","BK4198","BK4007","BK4531","BK4139","BK4585","ZTEK","NVO.AU","IBB","LU0154236417.USD","XLV","BK4548","NVO","BK4532","BK4526","ZLAB"],"gpt_icon":1},{"id":"2504160883","title":"Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2504160883","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504160883?lang=en_us&edition=fundamental","pubTime":"2025-01-17 23:20","pubTimestamp":1737127249,"startTime":"0","endTime":"0","summary":"Zai Lab  said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration.The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs, according to the company.KarXT, or xanomeline and trospium chloride, showed a reduction in positive and negative syndrome scale total score from baseline in the China phase 3 study, Zai Lab added.Shares of Zai Lab were up 2.1% in recent trading.Price: 25.91, Change: +0.53, Percent Change: +2.09","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZLAB","BK4526","BK4585","BK4139","BK4548","BK4531","BK4588"],"gpt_icon":0},{"id":"2504252163","title":"Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2504252163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504252163?lang=en_us&edition=fundamental","pubTime":"2025-01-17 21:35","pubTimestamp":1737120923,"startTime":"0","endTime":"0","summary":"In a report released on January 14, David Li from Bank of America Securities maintained a Buy rating on Zai Lab (ZLAB – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-zai-lab-zlab-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-zai-lab-zlab-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLAB"],"gpt_icon":0},{"id":"2504521941","title":"Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2504521941","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504521941?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:30","pubTimestamp":1737117000,"startTime":"0","endTime":"0","summary":"SHANGHAI & CAMBRIDGE, Mass., January 17, 2025----Zai Lab Limited  today announced that China’s National Medical Products Administration  has accepted the New Drug Application  for KarXT for the treatment of schizophrenia in adults.\"There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options,\" said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. \"In clinical trials, KarXT demonstrated statistically significant reductions of schizophrenia symptoms along with a tolerable safety profile. If approved, KarXT has the potential to redefine the treatment landscape.\". \"KarXT is the first new class of treatment for patients with schizophrenia in several decades,\" said Gang Wang, M.D., Dean of Beijing Anding Hospital, Capital Medical University and the leading principal investigator for the Phase 3 China study. \"We are excited a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-announces-acceptance-drug-123000556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4548","PK","ZLAB","BK4531","BK4585","BK4526","BK4218","BK4588","BK4181"],"gpt_icon":0},{"id":"2503965642","title":"Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2503965642","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503965642?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:31","pubTimestamp":1736951508,"startTime":"0","endTime":"0","summary":"Zai Lab  said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.Main secondary endpoints of progression-free survival and objective response rate also \"favored treatment with Tivdak compared to chemotherapy,\" Zai Lab said.The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.ZLAB shares were up 2.8% in early trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4531","BK4588","BK4548","BK4139","ZLAB","BK4526","BK4585"],"gpt_icon":0},{"id":"2503648177","title":"Zai Lab announces results from innovaTV 301 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503648177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503648177?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:42","pubTimestamp":1736944971,"startTime":"0","endTime":"0","summary":"Zai Lab (ZLAB) announced topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningf...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zai-lab-announces-results-from-innovatv-301-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zai-lab-announces-results-from-innovatv-301-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4548","BK4585","BK4588","ZLAB","BK4526","BK4531"],"gpt_icon":0},{"id":"2503648929","title":"Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503648929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503648929?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:30","pubTimestamp":1736944200,"startTime":"0","endTime":"0","summary":"Improved overall survival , progression-free survival  and confirmed objective response rate  were observed in the China subpopulation treated with TIVDAK compared to chemotherapy, consistent with those in the global population. The safety profile of TIVDAK among the China subpopulation was manageable and consistent with that observed in the global population. Zai Lab intends to submit a New Drug Application  to China’s National Medical Products Administration  in the first quarter of 2025. Zai Lab will leverage its commercial footprint of ZEJULA in women’s cancer to bring the medicine to patients in China if approved. \"There are approximately 150,000 new cases of cervical cancer annually in China1, and patients face limited treatment options once their cancer recurs or spreads after initial treatment,\" said Dr. Lingying Wu, Professor of the Department of Gynecologic Oncology of National Cancer Center / Cancer Hospital Chinese Academy of Medical Sciences. \"While the recent adoption of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-announces-positive-topline-123000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4526","LU1057294990.SGD","BK4139","SG9999011175.SGD","LU0225771236.USD","BK4533","PFE","OS","LU1066053197.SGD","BK4588","BK4534","LU0122379950.USD","LU0289739699.SGD","PFS","SG9999013999.USD","LU0321505439.SGD","LU1883839398.USD","SGXZ57979304.SGD","BK4581","BK4107","BK4599","L","LU0225284248.USD","LU0868494617.USD","LU0456855351.SGD","SG9999002232.USD","BK4231","ZLAB","IE00B19Z3B42.SGD","ADC","SG9999001176.SGD","BK4007","LU0170899867.USD","BK4550","LU0985481810.HKD","BK4531","SG9999003800.SGD","SG9999002224.SGD","BK4568","BK4097","BK4080","LU0058720904.USD","LU1894683348.USD","BK4195","IE0002270589.USD","BK4548","LU0306806265.USD","IE000M9KFDE8.USD","SG9999001176.USD","LU0306807586.USD"],"gpt_icon":1},{"id":"2503615800","title":"Bank of America Securities Keeps Their Buy Rating on Zai Lab (ZLAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503615800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503615800?lang=en_us&edition=fundamental","pubTime":"2025-01-15 18:17","pubTimestamp":1736936238,"startTime":"0","endTime":"0","summary":"In a report released on January 13, David Li from Bank of America Securities maintained a Buy rating on Zai Lab (ZLAB – Research Report), with a pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-keeps-their-buy-rating-on-zai-lab-zlab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-keeps-their-buy-rating-on-zai-lab-zlab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLAB","BAC"],"gpt_icon":0},{"id":"2503577931","title":"Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503577931","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503577931?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:03","pubTimestamp":1736863380,"startTime":"0","endTime":"0","summary":"Sage Therapeutics, Inc.  shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.1% gain over the past four weeks.The stock rallied after the company announced that its partner Biogen had made an unsolicited, non-binding proposal offer to acquire SAGE shares that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan 10.For Sage Therapeutics, the consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road.Sage Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-sage-moves-35-140300773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4526","BK4588","SAGE","BK4548","BK4531","BK4585","BK4139","ZLAB"],"gpt_icon":0},{"id":"2502803203","title":"Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502803203","media":"TipRanks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502803203?lang=en_us&edition=fundamental","pubTime":"2025-01-11 20:41","pubTimestamp":1736599281,"startTime":"0","endTime":"0","summary":"Zai Lab  and Vertex Pharmaceuticals  announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore. Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL being studied for the treatment of Immunoglobulin A nephropathy and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will be responsible for all commercialization activities in the licensed territory once povetacicept becomes an approved product.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Zai Lab enters Tmalin license agreement with MediLink ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/zai-lab-vertex-pharmaceuticals-announce-124121180.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-vertex-pharmaceuticals-announce-124121180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2417539215.USD","BK4567","LU1069344957.HKD","VERX","IE00BFTCPJ56.SGD","LU0566484027.USD","BK4139","VRTX","IE00B19Z9P08.USD","BK4533","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU2324357040.USD","BK4585","LU0256863811.USD","IE00BJT1NW94.SGD","BK4588","IE00B19Z3581.USD","BK4023","LU0234570918.USD","IE00B2B36J28.USD","LU0289739699.SGD","LU2362541513.USD","LU0417517546.SGD","LU1559883803.SGD","LU2456880835.USD","LU0823416689.USD","LU2236285917.USD","LU1035775433.USD","IE0002141913.USD","LU0058720904.USD","ZLAB","IE00B19Z9Z06.USD","LU1585245621.USD","IE0002270589.USD","LU0061475181.USD","IE00B894F039.SGD","LU2462157665.USD","BK4531","LU0889565916.HKD","LU0320765992.SGD","LU1430594728.SGD","BK4532","BK4526","IE00B4R5TH58.HKD","LU2237438978.USD","LU0079474960.USD","LU1093756168.USD","IE00B19Z3B42.SGD","IE0009355771.USD"],"gpt_icon":0},{"id":"2502789315","title":"Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2502789315","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502789315?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:36","pubTimestamp":1736523371,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were down Friday morning, dropping 2.09% to 2,039.73 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by brand platform 36Kr  and biotech company Zai Lab , which rose 2.8% and 1.7% respectively. They were followed by financial services company Shinhan Financial Group  and automotive ecommerce platform Cango , which were up 0.4% and 0.2% respectively.The decliners from North Asia were led by mobile app developer Cheetah Mobile  and online brokerage UP Fintech , which fell 7.1% and 6.9% respectively. They were followed by solar panel maker JinkoSolar  and health platform 111 , which dropped 6.1% each.From South Asia, the gainers were led by IT companies Sify Technologies  and Infosys , which increased 1.2% and 0.7% respectively. They were followed by IT firm Wipro  and telecommunications operator Telekomunikasi Indonesia , which were up 0.6% and 0.1% respectively.The decliners from South Asia were led by ph","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999013478.USD","LU0516422440.USD","LU0737861269.HKD","YI","LU0251143029.SGD","KRKR","AFG","LU2226246903.HKD","LU0531971678.HKD","INFY","SIFY","BK4566","JKS","LU0541502299.USD","CMCM","SHG.AU","WIT","LU0979878070.USD","BK4548","LU1854103824.USD","BK4023","SG9999014484.SGD","ZLAB","LU0181495838.USD","LU0572939691.SGD","BK4134","BK4532","HDB","RDY.AU","BK4214","SE","LU0264410563.USD","CANG","LU0143863198.USD","BK4117","LU0791591158.USD","BK4557","IBN","LU2087589342.USD","BK4600","TIGR","LU0261945553.USD","LU1854104046.USD","RDY","SHG","LU0536402901.SGD","NQGM","BK4503","SG9999013486.USD","TLK"],"gpt_icon":1},{"id":"2502863623","title":"Vertex, Zai Lab Partner Over Povetacicept Development in China, 4 Other Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2502863623","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502863623?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:13","pubTimestamp":1736514786,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  and Zai Lab  said Friday they have signed a licensing deal to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore.Zai Lab will oversee clinical trials, regulatory submissions, and marketing in the licensed territory, the companies said.Vertex will receive an upfront payment, regulatory milestone payments, and tiered royalties on net sales of the drug, they added.Vertex's Povetacicept is being studied for the treatment of1 Immunoglobulin A nephropathy and other B cell-mediated diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0079474960.USD","BK4588","LU2456880835.USD","LU0417517546.SGD","LU0061475181.USD","BK4585","LU2362540622.SGD","IE00BJJMRZ35.SGD","VERX","LU0109394709.USD","IE00B2B36J28.USD","BK4138","IE00B19Z3581.USD","LU0058720904.USD","IE00BZ9MQY76.HKD","IE0009355771.USD","RF","BK4139","LU2236285917.USD","LU2417539215.USD","IE00B19Z9Z06.USD","LU0823416689.USD","BK4211","LU1093756168.USD","BK4531","BK4526","IE0002270589.USD","ZLAB","LU0234570918.USD","IE0002141913.USD","BK4533","IE00B4R5TH58.HKD","BK4532","LU0256863811.USD","IE00BJT1NW94.SGD","VRTX","VTNR","LU2362541513.USD","IE00B894F039.SGD","LU0889565916.HKD","LU1035775433.USD","IE00B19Z3B42.SGD","BK4548","LU0289739699.SGD","LU1093756325.SGD","LU2362541273.HKD","BK4567","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","LU1585245621.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0125},{"period":"1month","weight":0.1329},{"period":"3month","weight":-0.1009},{"period":"6month","weight":0.6931},{"period":"1year","weight":0.4042},{"period":"ytd","weight":0.0512}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0043},{"period":"6month","weight":0.1272},{"period":"1year","weight":0.2056},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.10392},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017869},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.101183},{"month":4,"riseRate":0.428571,"avgChangeRate":0.026877},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03934},{"month":6,"riseRate":0.428571,"avgChangeRate":0.063316},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00593},{"month":8,"riseRate":0.714286,"avgChangeRate":0.018507},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.066935},{"month":10,"riseRate":0.5,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.625,"avgChangeRate":0.141461},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016217}],"exchange":"NASDAQ","name":"Zai Lab Ltd","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zai Lab Ltd(ZLAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zai Lab Ltd(ZLAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zai Lab Ltd,ZLAB,Zai Lab Ltd股票,Zai Lab Ltd股票老虎,Zai Lab Ltd股票老虎国际,Zai Lab Ltd行情,Zai Lab Ltd股票行情,Zai Lab Ltd股价,Zai Lab Ltd股市,Zai Lab Ltd股票价格,Zai Lab Ltd股票交易,Zai Lab Ltd股票购买,Zai Lab Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zai Lab Ltd(ZLAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zai Lab Ltd(ZLAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction